NEW YORK, July 11 – DoubleTwist of Oakland, Calif., said Wednesday that in the second quarter of 2001 it had signed more than 10 new subscribers to its genomic data and analysis tools available through DoubleTwist.com.
The news comes on the heels of a similar announcement made in April in which DoubleTwist said that it had signed 20 new subscribers in the first quarter of the year.
DoubleTwist did not comment on the subscription fees the new users were paying and a spokesperson was not immediately available for comment.
The spate of good news seems to mark a turnaround for the company, which was forced to cancel its IPO due to poor market conditions. Later, DoubleTwist cut its staff, triggering questions about whether or not the company would survive.
The new customers include Cedars Sinai Medical Center, DeveloGen, Icagen, Laboratoires Fournier, MD Anderson Cancer Center, The National Cancer Institute, Organon, Oxagen, Pherin Pharmaceuticals, Provalis, Switch Biotech, The University of California at Davis, The University of Reading, The Weizmann Institute of Science, and a number of unnamed organizations in Europe and Asia.